Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 10, 2016, Pages 1112-1122

  McMillan, Corey T ^a   Wolk, David A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOE PROTEIN, HUMAN; APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; AMYLOIDOSIS; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN STEM; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GRAY MATTER; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TEMPORAL CORTEX; BRAIN; BRAIN DISEASES; BRAIN MAPPING; CEREBROSPINAL FLUID; COMPUTER ASSISTED DIAGNOSIS; DISABILITY; DISEASE COURSE; GENETICS; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHENOTYPE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; STATISTICS; THREE DIMENSIONAL IMAGING;

ADULT; AGED; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; APOLIPOPROTEINS E; BRAIN; BRAIN DISEASES; BRAIN MAPPING; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHENOTYPE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 84973531032     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-312690     Document Type: Article

References (40)

1. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-7
2. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11
3. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13
4. Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson's disease dementia: convergence of α-synuclein, tau, and amyloid-β pathologies. Nat Rev Neurosci 2013; 14: 626-36
5. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm Gen Sect 2004; 111: 1219-35
6. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587-98
7. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055-61
8. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134: 1493-505
9. Clinton LK, Blurton-Jones M, Myczek K, et al. Synergistic Interactions between Aβ, Tau, and α-synuclein: acceleration of neuropathology, and cognitive decline. J Neurosci 2010; 30: 7281-9
10. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation, and neuronal deficits in a transgenic mouse model linking Alzheimer's disease, and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 12245-50
11. Kang J-H, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013; 70: 1277-87
12. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-35
13. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid, and neuropsychological functions in Parkinson's disease. Mov Disord 2009; 24: 2203-10
14. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta, and tau proteins, and cognitive performance, in early, and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatr 2010; 81: 1080-6
15. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13
16. Shapiro AM, Benedict RH, Schretlen D, et al. Construct, and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 1999; 13: 348-58
17. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch Neurol 1978; 35: 364-7
18. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22: 41-7
19. Klein A, Ghosh SS, Avants B, et al. Evaluation of volume-based, and surface-based brain image registration methods. Neuroimage 2010; 51: 214-20
20. Tustison NJ, Cook PA, Klein A, et al. Large-scale evaluation of ANTs, and FreeSurfer cortical thickness measurements. Neuroimage 2014; 99: 166-79
21. Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 2010; 29: 1310-20
22. Avants BB, Tustison NJ, Wu J, et al. An open source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics 2011; 9: 381-400
23. Radua J, Canales-Rodríguez EJ, Pomarol-Clotet E, et al. Validity of modulation, and optimal settings for advanced voxel-based morphometry. Neuroimage 2014; 86: 81-90
24. Klein A, Tourville J. 101 labeled brain images, and a consistent human cortical labeling protocol. Front Neurosci 2012; 6: 171
25. Wilson RS, Schneider JA, Bienias JL, et al. Parkinsonian like signs, and risk of incident Alzheimer disease in older persons. Arch Neurol 2003; 60: 539-44
26. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-31
27. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-12
28. Nalls MA, Plagnol V, Hernandez DG, et al., International Parkinson Disease Genomics Consortium. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377: 641-9
29. Tsuang D, Leverenz JB, Lopez OL, et al. APOE 4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70: 223-8
30. Mollenhauer B, Trautmann E, Taylor P, et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013; 532: 44-8
31. Stewart T, Sossi V, Aasly JO, et al. Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun 2015; 3: 7
32. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
33. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26: 1183-92
34. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012; 209: 975-86
35. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014; 83: 406-12
36. Kulisevsky J. Role of dopamine in learning, and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000; 16: 365-79
37. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67: 949-56
38. Petrou M, Bohnen NI, M?ller MLTM, et al. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012; 79: 1161-7
39. Buddhala C, Campbell MC, Perlmutter JS, et al. Correlation between decreased CSF α-synuclein, and Aβ1-42 in Parkinson disease. Neurobiol Aging 2015; 36: 476-84
40. Petrou M, Dwamena BA, Foerster BR, et al. Amyloid deposition in Parkinson's disease, and cognitive impairment: a systematic review. Mov Disord 2015; 30: 928-35